Of note, high levels of amplitude (CN>12) of COPS5 are significantly enriched in the ERα+ breast cancer patients, implicating that the amplification and overexpression of COPS5 may contribute to the ERα-related signalling and tumour progression (Fig. 1c, Supplementary Table 1). Here, ESR1 is linked to breast cancer.